Speaker Profile
Ph.D., CEO, Insilico Medicine
Biography
Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine, a leading clinical-stage biotechnology company developing next-generation generative artificial intelligence and robotics platforms for drug discovery. Under his leadership, Insilico raised over $400 million in multiple rounds from expert biotechnology, healthcare, and financial investors, opened RD centers in 6 countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions. Since 2021, the company nominated 21 preclinical candidates, started 6 human clinical trials, and entered Phase II with an AI-discovered novel target and AI-designed novel molecule. Since 2012, he has published over 200 peer-reviewed research papers and 3 books. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Michael Goldman, SFSU
PMWC Award Ceremony
• David Sinclair, Harvard
• Steve Horvath, UCLA
• Nir Barzilai, Albert Einstein College of Medicine
AI-Driven Biomarkers to Quantify Aging
• Chair: Alex Zhavoronkov, Insilico Medicine
• Luigi Ferrucci, NIH
• Sara Hägg, Karolinska Institutet
• Steve Horvath, UCLA
Epigenetic Aging Signatures in Large Human Cohorts
• Varun Dwaraka, Trudiagnostic
AI Systems for Personalized Longevity: How Biomarkers Translate into Actionable Interventions
• Sherry Zhang, Buck Institute
• Nathan Price, THORNE
• Ranjan Sinha, digbi Health
Epigenetic Rejuvenation & Delivery for Clinical Translation
• Ryan (Yuancheng) Lu, Whitehead Institute/MIT
• David Sinclair, Harvard
Clinical Trial Design & Functional Endpoints for Healthspan
• Nir Barzilai, Albert Einstein College of Medicine
Precision Aging & Longevity: Limited Lifespan Evidence, Vanishing Blue Zones, and Payer ROI
• S. Jay Olshansky, University of Illinois
• Michael Gurven, UC Santa Barbara
